A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Completed · Phase 3

Conditions studied: Acute Myeloid Leukemia (AML), Cancer

In brief

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.

Key facts

Study ID

NCT03941964

Run by

AbbVie

People needed

60

Starts

2019-08-15

Expected to finish

2022-03-14

Last updated by the study team

2023-03-20

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria
• Participant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax
• Participant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens
• Participant has not received prior treatment for AML (treatment naïve) with the exception of hydroxyurea
• Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening
• Participant can have progressed from myelodysplastic syndrome (MDS) or be considered to have secondary AML and could have been treated with growth factors or other agents with the exception of hypomethylating agents
• Participant has adequate kidney, liver, and hematology laboratory values as detailed in the protocol
• Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3

You may not qualify if…

• Has a history of the following conditions:
• Acute promyelocytic leukemia
• Known active central nervous system involvement with AML
• Positive for HIV (HIV testing is not required)
• Positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months
• Cardiovascular disability status of New York Heart Association Class > 2
• Chronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study
• Malabsorption syndrome or other condition that precludes enteral route of administration
• Has a history of other malignancies within 2 years prior to study entry, with the exception of:
• Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast
• Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
• Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent

Where it is running

• Arizona Oncology Associates, PC-HOPE /ID# 211509 — Tempe, Arizona, United States
• Colorado Blood Cancer Institute /ID# 212800 — Denver, Colorado, United States
• Rocky Mountain Cancer Centers /ID# 211508 — Lone Tree, Colorado, United States
• Fort Wayne Medical Oncology /ID# 223523 — Fort Wayne, Indiana, United States
• Minnesota Oncology Hematology, PA /ID# 212837 — Minneapolis, Minnesota, United States
• Oncology Hematology Care, Inc. /ID# 212779 — Cincinnati, Ohio, United States
• Willamette Valley Cancer Institute and Research Center /ID# 211504 — Eugene, Oregon, United States
• Charleston Oncology, P.A. /ID# 211471 — Charleston, South Carolina, United States
• Prisma Health Cancer Inst - Eastside /ID# 211466 — Greenville, South Carolina, United States
• Tennessee Oncology - Chattanooga / McCallie /ID# 212717 — Chattanooga, Tennessee, United States
• Tennessee Oncology-Nashville Centennial /ID# 210944 — Nashville, Tennessee, United States
• Texas Oncology - Austin Midtown /ID# 212780 — Austin, Texas, United States
• Texas Oncology - Medical City Dallas /ID# 211503 — Dallas, Texas, United States
• Texas Transplant Institute /ID# 213311 — San Antonio, Texas, United States
• Texas Oncology - San Antonio Medical Center /ID# 211510 — San Antonio, Texas, United States
• Texas Oncology - Northeast Texas /ID# 213908 — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.